Key result
Higher medication adherence via electronic pill bottles is linked to ~69% lower vascular readmission or death.
Why the study?
Medication adherence after myocardial infarction remains low and pharmacy claims have typically been used to measure adherence, but electronic pill bottles may provide additional information.
Does medication adherence monitoring using electronic pill bottles compared to pharmacy claims better predict time to first vascular readmission or death in myocardial infarction patients?
RCT (n=682)
randomized
Does medication adherence monitoring using electronic pill bottles compared to pharmacy claims better predict time to first vascular readmission or death in myocardial infarction patients?
Hazard Ratio: 0.313
p-value: p=≤0.001
Electronic pill bottles provide additional prognostic information beyond pharmacy claims for predicting vascular readmission or death in post-myocardial infarction patients.
May aid post-MI risk stratification beyond pharmacy claims; hypothesis-generating for prospective trials.
BACKGROUND: Medication adherence after myocardial infarction remains low. Pharmacy claims have typically been used to measure medication adherence, but electronic pill bottles may offer additional information. OBJECTIVE: The main objectives of this study were to compare the association of adherence measured by prescription claims and remote monitoring technologies with cardiovascular events. RESEARCH DESIGN: This study was a secondary analysis of a remote monitoring intervention to increase medication adherence in myocardial infarction patients. SUBJECTS: In total, 682 myocardial infarction patients were randomized to the intervention group with both medical and pharmacy benefits. MEASURES: Pharmacy claims adherence was measured using proportion of days covered (PDC) and GlowCap adherence (GC) was measured as the proportion of days the pill bottle was opened. We compared the association of PDC and GC adherence for statins with time to first vascular readmission or death and assessed model fit using Akaike information criterion and Bayesian information criterion and the likelihood ratio test. RESULTS: Higher PDC was significantly associated with a lower hazard rate for vascular readmissions or death (hazard ratio=0.435; P=0.009). There was also an association between GC adherence and vascular readmissions or death (hazard ratio=0.313; P≤0.001). Adding the GC adherence variable to the model using only PDC improved the model fit (likelihood ratio test, P=0.001), as well as vice versa (P=0.050). CONCLUSIONS: Pharmacy claims data provide useful but not complete data for medication adherence monitoring. New wireless technologies have the potential to provide additional data about clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2018) conducted an RCT in Myocardial infarction (n=682). Electronic pill bottles (GlowCap) vs. Pharmacy claims (PDC) was evaluated on Time to first vascular readmission or death (HR 0.313, p=≤0.001). Higher medication adherence measured by electronic pill bottles (GlowCap) was significantly associated with a lower hazard of vascular readmission or death (HR 0.313; P≤0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: